Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 561 to 570 of 1447 total matches.
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016 (Issue 1487)
doses up to 1.2 and 2.9 times, respectively, the
18
The Medical Letter ® Vol. 58 (1487) February 1 ...
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with cancer
chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) and netupitant (only available
in combination with the 5-HT3 receptor antagonist
palonosetron as Akynzeo) were approved earlier for
prevention of both acute and delayed chemotherapy-induced
nausea and vomiting.
Elvitegravir (Vitekta) for HIV
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
Letter ® Vol. 58 (1486) January 18, 2016
virologically active PI and another virologically active ...
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of HIV-1 infection
in treatment-experienced adults. Elvitegravir is also
available in a fixed-dose combination (Stribild) with
the pharmacokinetic enhancer cobicistat and the
nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (DF). A similar combination (Genvoya) that
includes tenofovir alafenamide instead of tenofovir...
Mepolizumab (Nucala) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
The Medical Letter ® Vol. 58 (1486) January 18, 2016
discontinuation of the drug, and exacerbation rates ...
The FDA has approved mepolizumab (Nucala - GSK), a
subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance
treatment of severe asthma in patients ≥12 years old
who have an eosinophilic phenotype.
Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
) or another antiviral
drug could interfere with the effectiveness of T-VEC.
9
The Medical Letter ® Vol. 58 ...
The FDA has approved talimogene laherparepvec
(Imlygic – Amgen), a genetically modified herpes
simplex virus, for intralesional treatment of
unresectable cutaneous, subcutaneous, and nodal
lesions in patients with melanoma that has recurred
following surgery. It is the first oncolytic virotherapy to
become available in the US.
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
Excretion Feces (82.2%); urine ( ...
The FDA has approved eluxadoline (Viberzi – Actavis),
a mu-opioid receptor agonist and delta-opioid
receptor antagonist, for oral treatment of adults with
irritable bowel syndrome with diarrhea (IBS-D).
Naloxone (Narcan) Nasal Spray for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
is an exception, with a half-
2
The Medical Letter ® Vol. 58 (1485) January 4, 2016
Additional doses can ...
The recent increase in deaths due to overdose of
heroin and prescription opioids in the US has renewed
interest in the opioid antagonist naloxone, particularly
in making it available to first responders and to
relatives and close friends of persons using heroin or
taking prescription opioids. IV or IM administration
by healthcare professionals is preferred, but
peripheral venous access may be difficult to obtain
in IV drug abusers, and exposure to their blood may
be hazardous.
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
mg for ambrisentan and 40 mg for tadalafil.
3
The Medical Letter ® Vol. 58 (1485) January 4, 2016 ...
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this indication.
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
® Vol. 57 (1484) December 21, 2015
not apply to patients with type 2 diabetes and less
advanced ...
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor empagliflozin
(Jardiance) and metformin (Glucophage, and others),
for treatment of patients with type 2 diabetes not
adequately controlled on either of these drugs alone
or already being treated with both empagliflozin and
metformin. It is the third SGLT2 inhibitor/metformin
combination to be approved in the US.
Intravenous Diclofenac (Dyloject)
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
The Medical Letter ® Vol. 57 (1484) December 21, 2015
were superior to those with placebo for all scheduled ...
The FDA has approved Dyloject (Hospira), an IV
formulation of the NSAID diclofenac sodium, for use
in adults. It can be administered alone for treatment
of mild to moderate pain or in combination with opioid
analgesics for moderate to severe pain. Dyloject is the
first injectable formulation of diclofenac to become
available in the US.
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
-
policy.
169
The Medical Letter ® Vol. 57 (1483) December 7, 2015 ipilimumab melanoma nivolumab Opdivo ...
The FDA has approved the combined use of the
programmed death receptor-1 (PD-1) blocking
antibody nivolumab (Opdivo) and the anti-CLA-4
antibody ipilimumab (Yervoy) for treatment of BRAF
V600 wild-type unresectable or metastatic melanoma.
This is the first immunotherapy combination to be
approved for treatment of any type of cancer.